3,4-MDPV Stats - Substance Search

Effect Profile

Curated + 72 Reports

Stimulant 8.8

Strong stimulation, euphoria, and focus with strong anxiety/jitters

Stimulation / Energy×3

109.5

Euphoria / Mood Lift×2

107.1

Focus / Productivity×2

105.0

Anxiety / Jitters×1

1010

Catalog Erowid

Based on reports from:

Erowid Experience Reports PsychonautWiki 3,4-MDPV

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 4d Baseline ~5d

Experience Report Analysis

Erowid

105 Reports

72 Single-substance

2005–2017 Date Range

87 With Age Data

27 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 72 experience reports (72 single-substance Erowid)

72 Reports

27 Effects Detected

9 Positive

12 Adverse

6 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Positive Effects 9

Stimulation 55.6% 70%

Euphoria 47.2% 70%

Empathy 26.4% 70%

Focus Enhancement 25.0% 70%

Music Enhancement 12.5% 70%

Color Enhancement 11.1% 70%

Introspection 6.9% 70%

Creativity Enhancement 4.2% 70%

Tactile Enhancement 4.2% 70%

Adverse Effects 12

Anxiety 45.8% 70%

Increased Heart Rate 19.4% 70%

Confusion 16.7% 70%

⚠ Psychosis 12.5% 70%

Headache 12.5% 70%

Nausea 9.7% 70%

Jaw Clenching 8.3% 70%

Sweating 8.3% 70%

Pupil Dilation 6.9% 70%

Muscle Tension 5.6% 70%

Memory Suppression 4.2% 70%

Motor Impairment 4.2% 70%

Show 6 neutral or unclassified mentions

Sedation 15.3%

Hospital 12.5%

Auditory Effects 11.1%

Dissociation 6.9%

Visual Distortions 5.6%

Open-Eye Visuals 5.6%

Also reported in combinations. In the 33 3,4-MDPV reports where another drug was taken too, 3 (9.1%) mention hospital, emergency services or an overdose, 0 (0.0%) a seizure and 3 (9.1%) psychosis. In the 72 single-substance reports: 12.5%, 2.8% and 12.5%. These are not in the figures above: they cannot be put down to 3,4-MDPV alone, and a mention is not always something that happened to the writer.

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Median: 8.5 mg IQR: 5.0–10.0 mg n=18

1 report gave a dose above the typical range (125 mg), so it is not in the figures above. Listing a dose here does not mean it is safe.

Show the report

125 mg

Common Combinations

Most co-occurring substances, as a share of all 105 reports filed under 3,4-MDPV; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 71 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Median: 0.11 mg/kg IQR: 0.067–0.13 mg/kg n=18

1 report gave a dose above the typical range (1.532 mg/kg), so it is not in the figures above. Listing a dose here does not mean it is safe.